Dermatology最新文献

{"title":"The Burden of Chronic Spontaneous Urticaria: A Narrative Literature Review.","authors":"Chien-Chia Chuang, Jennifer Boss, Ryan B Thomas","doi":"10.1159/000553409","DOIUrl":"10.1159/000553409","url":null,"abstract":"<p><strong>Background: </strong>Chronic spontaneous urticaria (CSU) accounts for most cases of chronic urticaria; however, the prevalence and disease burden are not well characterized.</p><p><strong>Summary: </strong>A narrative literature review based on structured and targeted searches of the literature and iterative hand searches based on expert knowledge was conducted to assess the epidemiology and humanistic burden of CSU. Targeted searches were conducted in EMBASE (including conference abstracts), MEDLINE, and health technology agencies using a combination of terms related to \"chronic spontaneous urticaria\" between January 1, 2010, and June 13, 2023.</p><p><strong>Key messages: </strong>The searches retrieved a total of 62 articles. CSU prevalence was reported at 0.08%-2% across Asia, Europe/UK, North America, and South America. Risk factors reported for CSU included female sex, older age, and autoimmune conditions. Itch was the primary and most troublesome symptom. CSU has a significant burden on physical and mental health-related quality of life (HRQoL). Healthcare resource utilization (HCRU) in patients with CSU was driven by outpatient physician office and emergency department visits. Poorly controlled CSU led to greater impact on HRQoL and HCRU. In total, 24 articles reported on available treatment approaches and/or emerging therapies that target the underlying pathophysiology of CSU. Significant evidence gaps were identified, including the need for epidemiological data from a wider range of geographic regions and economic and cost-of-illness analyses. This narrative literature review demonstrates that CSU is associated with a significant burden of symptoms, reduced HRQoL, and HCRU. Early and appropriate diagnosis and new, effective treatment options are needed for patients with CSU.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-14"},"PeriodicalIF":3.6,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriatic Patients with Cancer: A Multicentric Real-Life Study Comparing Risankizumab and Apremilast.","authors":"Annunziata Raimondo, Anna Balato, Claudio Guarneri, Luigi Ligrone, Raffaella Manzo, Matteo Megna, Maria Letizia Musumeci, Giovanni Palazzo, Rosa Valentina Puca, Francesca Romano, Serena Lembo","doi":"10.1159/000553458","DOIUrl":"10.1159/000553458","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence on the management of psoriasis in patients with a recent history of malignancy is limited, and safety data on systemic and biologic therapies in this setting are very important. Recent studies confirm the safety of anti-interleukin (IL) biological drugs in patients with psoriasis and a personal history of cancer. This report presents the safety and effectiveness assessments of risankizumab (RISA) and apremilast (APRE) in psoriatic patients with a recent cancer diagnosis (<5 years) in a real-world setting.</p><p><strong>Methods: </strong>This retrospective, multicentre, observational study includes adult patients with psoriasis and recent oncologic history treated with RISA or APRE. Clinical characteristics, treatment safety, including cancer recurrence/progression, and effectiveness outcomes were collected during follow-up.</p><p><strong>Results: </strong>Eighty-seven patients were included (RISA n = 21; APRE n = 66) in this study. Baseline characteristics were broadly comparable, although prior biologic exposure was more frequent in the RISA group. Over a mean follow-up of 30 months, both treatments showed acceptable safety profiles. No cancer recurrence or progression occurred in the RISA group, while one event was observed in the APRE group. Due to the extremely low number of oncologic events, analyses were descriptive. Risankizumab showed a higher effectiveness than apremilast, with a significant improvement also in quality of life and well-being.</p><p><strong>Conclusions: </strong>In this multicentre real-world cohort of psoriatic patients with recent malignancy, risankizumab and apremilast showed favourable safety during the study follow-up. Larger studies with longer follow-up are needed.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.6,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunocryosurgery as Primary Treatment for Lentigo Maligna and as an Adjuvant Therapy for Lentigo Maligna Melanoma: A 21-Patient Case Series.","authors":"Guillem Esteve-Boncompte, Aina Sánchez-Quin, Yomara Morant, Felip Vilardell, Xavier Soria, Rosa M Torrente, Maria Jaria, Valentín Huerva, Rosa M Marti","doi":"10.1159/000553517","DOIUrl":"10.1159/000553517","url":null,"abstract":"<p><strong>Introduction: </strong>Lentigo maligna (LM) and lentigo maligna melanoma (LMM) often occur in cosmetically sensitive areas and may affect patients who are unsuitable for extensive surgery. This study evaluated immunocryosurgery as a primary treatment for LM and as adjuvant therapy after excision of the invasive component in LMM.</p><p><strong>Methods: </strong>This retrospective case series included 21 patients treated between 2015 and 2024, comprising 16 patients with histologically confirmed LM and 5 with histologically confirmed LMM. LM lesions were treated with immunocryosurgery alone, whereas LMM cases underwent limited excision of the invasive focus followed by adjuvant immunocryosurgery. The protocol consisted of a 3-week induction phase with daily topical imiquimod 5%, a single cryosurgery session without interrupting imiquimod, and 6 months of maintenance imiquimod. Patients were followed clinically and dermoscopically for recurrence, adverse events, and cosmetic outcomes.</p><p><strong>Results: </strong>After a median follow-up of 31 months, no recurrence occurred among patients with LM. Among patients with LMM, one developed local recurrence at 21 and 96 months, both of which were successfully retreated with the same regimen. Another patient developed a suspected local recurrence at 23 months that was treated empirically, with no further recurrence after 100 months of follow-up. All patients completed treatment, although temporary treatment interruptions occurred in 42.9%. Cosmetic outcomes were rated as excellent or good in 90.5% of cases. No melanoma-related deaths occurred.</p><p><strong>Conclusion: </strong>Immunocryosurgery provided durable local control and favorable cosmetic outcomes in this case series. It may represent a treatment option for selected patients with LM or LMM who are unsuitable for conventional surgery.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-8"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic disease prevalence by nativity, citizenship, and years of residence in the United States.","authors":"Vineeth R Vaidyula, Mohnish Alishala, Helga L Karadottir, Benjamin Ungar, Nicholas Gulati, Jonas A Adalsteinsson","doi":"10.1159/drm/ackag003","DOIUrl":"10.1159/drm/ackag003","url":null,"abstract":"<p><strong>Introduction: </strong>Although atopic disease, including atopic dermatitis (AD), asthma, and allergic rhinitis, is less prevalent among immigrants than natives in developed nations, its prevalence is poorly characterized among US immigrants. In this study, we investigated the individual and joint effects of nativity, US citizenship, and duration of US residence on the prevalence of atopic disease among US adults.</p><p><strong>Methods: </strong>We analyzed 25,597 US-born and 4,714 immigrant sample adults from the 2024 National Health Interview Survey. We generated nationally-representative prevalence estimates and fitted sociodemographic-adjusted multivariable logistic regression models.</p><p><strong>Results: </strong>Compared to US-born individuals, immigrants reported less AD (4.5% vs 8.5%; aOR: 0.56, 95% CI: [0.45-0.70]). Noncitizens also reported less AD (aOR: 0.38 [0.28-0.52]) than citizens. Moreover, compared to US-born participants, immigrant noncitizens (2.5%; aOR: 0.33 [0.23-0.45]) reported less AD than immigrant citizens (6.2%; aOR: 0.68 [0.54-0.87]). Compared to US-born participants, immigrants residing <15 years in the US (4.2%; aOR: 0.47 [0.32-0.69]) reported less AD than immigrants with ≥15 years of residence (4.7%; aOR: 0.60 [0.48-0.75]); longer US residence may erode the protective effect of immigration via immigrants' gradual adoption of US-specific health behaviors, including proinflammatory diets and obesity, increasing AD risk. In joint stratification analysis, AD prevalence increased progressively from recent immigrant noncitizens (2.7%; aOR: 0.30 [0.19-0.45]) to long-term immigrant citizens (5.7%; aOR: 0.64 [0.51-0.81]), and ultimately US-born citizens (8.5%; reference level), suggesting a dose-dependent relationship between acculturation and AD risk. Study limitations include self-reported outcomes. Results were similar for asthma, allergic rhinitis, and overall atopic disease.</p><p><strong>Conclusions: </strong>Early-life environmental exposures abroad may promote immune profiles associated with reduced AD risk. Longer US residence may erode the protective effect of immigration via immigrants' gradual adoption of US-specific health behaviors, including proinflammatory diets and obesity, increasing AD risk. Our results demonstrate a dose-dependent relationship between acculturation and atopic disease risk. Study limitations include self-reported outcomes. Citizenship demonstrated greater differences in outcomes than duration of US residence, suggesting it may capture additional factors influencing variation in atopic disease and merits further study.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the Cochrane Library: Interventions for Itch in People with Advanced Chronic Kidney Disease.","authors":"Rachel K Lim, Katie A O'Connell, Benjamin Gallo Marin, Athira Sivadas, Tyler C Beck, Leslie Robinson-Bostom, Shawn G Kwatra, Angela C Webster, Robert P Dellavalle","doi":"10.1159/000551999","DOIUrl":"10.1159/000551999","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-4"},"PeriodicalIF":3.6,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Dermatology Is for All Dermatologists.","authors":"Abitha Illango, Ditte Marie L Saunte","doi":"10.1159/000551178","DOIUrl":"10.1159/000551178","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-2"},"PeriodicalIF":3.6,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eczematous Component in Psoriasis is Possibly a Negative Prognostic Factor for Deucravacitinib Treatment Outcome.","authors":"Neda Cramer, Daniel Kromer, Johannes Mohr, Phoebe Wellmann, Natalija Novak, Rotraut Mössner, Dagmar Wilsmann-Theis","doi":"10.1159/000551738","DOIUrl":"10.1159/000551738","url":null,"abstract":"<p><strong>Introduction: </strong>Eczematized psoriasis is a clinical variant of psoriasis characterized by overlapping features of both psoriasis and eczema. Deucravacitinib is the first oral Janus kinase inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. The aim of this study was to investigate and compare the efficacy of deucravacitinib in patients with classical and eczematized psoriasis in real world.</p><p><strong>Methods: </strong>Patients with psoriasis who received deucravacitinib therapy in the dermatology department of two German University Medical Centers between 03/2023 and 03/2025 were included in this retrospective study. Treatment outcomes and drug survival of deucravacitinib was assessed with Kaplan-Meier analysis.</p><p><strong>Results: </strong>A total of 38 patients were identified (19 with classical psoriasis and 19 with eczematized psoriasis). Median drug survival of deucravacitinib was numerically higher in classical compared to eczematized psoriasis (21.0 vs. 6.0 months, p = 0.056). Partial or excellent response was more frequently observed in patients with classical psoriasis (68.4% vs. 47.4%). Relapses during treatment occurred significantly more frequently in eczematized than in classic psoriasis (57.9% vs. 26.3%, p = 0.033).</p><p><strong>Conclusion: </strong>The presence of an eczematous component in patients with psoriasis could adversely affect the treatment response to deucravacitinib and should be further investigated.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descriptive Analysis of Reports of Drug Reaction with Eosinophilia and Systemic Symptoms from EudraVigilance and from the RegiSCAR Project.","authors":"Diana Dubrall, Maren Paulmann, Wilma Fischer-Barth, Jens Bate, Matthias Schmid, Bernhardt Sachs, Maja Mockenhaupt","doi":"10.1159/000552416","DOIUrl":"10.1159/000552416","url":null,"abstract":"<p><strong>Introduction: </strong>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a T-cell-mediated severe cutaneous adverse reaction (SCAR) to drugs. Due to its rarity, there are currently only a few studies which include a larger number of cases. We sought to analyze a larger number of DRESS cases to increase knowledge of clinical symptoms, causative agents, and potentially associated factors.</p><p><strong>Methods: </strong>This is a non-interventional, retrospective, pharmacoepidemiological study analyzing descriptively DRESS reports in the EudraVigilance ADR database (EV) and DRESS cases in the registry of dZh/RegiSCAR. The two databases were analyzed separately, and the results were compared thereafter to identify both similarities and differences.</p><p><strong>Results: </strong>48 cases from EV and 84 RegiSCAR cases were included for the in-depth analysis. The liver was the most frequently involved inner organ. Most of the reactions occurred within 6 weeks after initiating the suspected inducing agent. The percentage of cases with fatal outcome was similar in both datasets (EV: 4.2%, RegiSCAR: 3.6%). Antiseizure drugs - especially carbamazepine - were most frequently involved in both datasets. In 4 reports from EV and 5 cases from RegiSCAR, sulfasalazine was identified as causative agent. Remarkably, all patients with sulfasalazine-induced DRESS were females with arthritic disease who were clearly younger compared to patients of the whole dataset.</p><p><strong>Conclusion: </strong>Our study confirms results obtained from other studies regarding the frequent involvement of the liver, the time to onset, and DRESS-inducing drugs. Further studies are needed to investigate whether younger female with arthritic disease may carry a higher risk to develop DRESS or whether other factors might be responsible for this observation.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-19"},"PeriodicalIF":3.6,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of the Vagus Nerve and Its Stimulation in Modulating Inflammatory Skin Diseases and Other Dermatologic Conditions: From Mechanisms to Therapeutics.","authors":"William J Nahm, Vincent Falanga, Ki-Joong Kim, Eui Namgung, John Koo","doi":"10.1159/000552415","DOIUrl":"https://doi.org/10.1159/000552415","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory skin diseases typically exhibit autonomic imbalance characterized by sympathetic dominance and parasympathetic hypofunction. The vagus nerve plays a fundamental role in modulating inflammatory responses through the cholinergic anti-inflammatory pathway, a neural circuit in which vagal efferent signals lead to acetylcholine release that suppresses pro-inflammatory cytokine production, and hypothalamic-pituitary-adrenal axis (HPA).</p><p><strong>Summary: </strong>This review analyzes emerging evidence supporting vagus nerve stimulation (VNS) as a therapeutic approach for inflammatory skin diseases. We reviewed preclinical studies and published clinical reports examining the effects of invasive and non-invasive VNS on inflammatory skin conditions and associated biomarkers. Recent research demonstrates that VNS can reset a dysregulated HPA axis and reduces inflammatory cascades by inhibiting inflammasome activation, attenuating pro-inflammatory cytokine synthesis, and accelerating inflammation resolution. Preclinical studies show that both invasive and non-invasive VNS significantly attenuate inflammatory markers in mouse models of psoriasis, eczema, and vitiligo, despite the skin lacking direct vagal innervation. Published reports document notable improvement in seborrheic dermatitis and rosacea following transcutaneous VNS. Inflammatory skin diseases share similar comorbidity profiles with conditions directly linked to vagal dysregulation, suggesting a common pathophysiological framework defined by impaired neuroimmune communication. The \"Cutaneous Vagal Dysregulation Inflammatory Axis\" views inflammatory skin disorders as resulting from a bidirectional relationship in which autonomic imbalance promotes a pro-inflammatory state across multiple organ systems.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-31"},"PeriodicalIF":2.7,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant Extracts in Acne Management: A Narrative Review.","authors":"Mathieu Leti, Lucile Garidou, Stéphane V Cuisiat, Aline Stennevin, Gautier Doat, Céline Mias","doi":"10.1159/000547149","DOIUrl":"10.1159/000547149","url":null,"abstract":"<p><strong>Background: </strong>Acne is a chronic inflammatory skin disease associated with impaired pilosebaceous unit function, leading to the development of noninflammatory and inflammatory lesions and, in some cases, persistent post-inflammatory erythema, hyperpigmentation, and scarring. Acne pathophysiology is complex, involving altered sebum production and composition, abnormal keratinization, microbiome dysbiosis, and skin inflammation. Conventional therapies, such as topical retinoids, antibiotics, and benzoyl peroxide, are the first-line treatments for mild-to-moderate acne, but antibiotic resistance and local adverse effects can have a negative impact on therapeutic outcomes, leading to a growing interest in alternative strategies for disease management. The use of dermocosmetics is increasingly being recognized as a useful strategy to improve treatment outcomes and patient adherence. In particular, there has been a recent increase in research aiming to identify natural plant-based ingredients with properties that target the multiple pathogenic mechanisms involved in acne but which have less impact on skin barrier function.</p><p><strong>Summary: </strong>This review provides a summary of the anti-acne properties of the most well-characterized plant extracts and phytocompounds used in dermocosmetic anti-acne products, based on insights gained from in vitro, ex vivo, and in vivo studies. Evidence gained from clinical trials evaluating the effectiveness and safety of topical formulations containing these herbal ingredients is also presented. Finally, several less well-characterized herbal extracts and phytocompounds with promising anti-acne properties are described.</p><p><strong>Key messages: </strong>Although research is ongoing for many of the anti-acne herbal ingredients identified so far, this review highlights the effectiveness of topical plant-based formulations for reducing lesion counts and disease severity in acne patients, as well as the rebalancing effects of herbal ingredients on sebum composition, microbial diversity, and pilosebaceous unit cell differentiation. Taken together with the antibiofilm, anti-inflammatory, antioxidant, and skin barrier repair properties demonstrated for many of these extracts, current evidence suggests that dermocosmetics with plant-based ingredients show great promise for acne management, either as monotherapies, maintenance treatments, or in combination with conventional drugs.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"25-65"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}